A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

NCT03698305 | Completed Phase 1 FDA Drug

• 1 other identifier: 5354-CL-0001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to assess the safety and tolerability of ASP5354 administered intravenously as a single dose to healthy subjects. This study will also assess the single dose pharmacokinetics of ASP5354 in plasma and urine.

Conditions

Healthy Subjects

Keywords

Tolerability; Pharmacokinetics; Safety; ASP5354

Outcome Measures

Primary Outcomes (5)

• Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs)

  An AE is any untoward medical occurrence in a participants administered ASP5354, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. AEs will be coded using MedDRA.

  Up to Day 14

• Number of participants with laboratory value abnormalities and/or AEs

  Number of participants with potentially clinically significant laboratory values.

  Up to Day 7

• Number of participants with vital sign abnormalities and /or AEs

  Number of participants with potentially clinically significant vital sign values.

  Up to Day 7

• Safety and tolerability assessed by 12-lead electrocardiogram (ECG)

  12-lead ECGs will be taken after the subject has been resting in the supine position for at least 5 minutes. 12 lead ECGs will be taken in triplicate.

  Up to Day 7

• Number of participants with physical exam abnormalities and/or adverse events (AEs)

  Number of participants with potentially clinically significant physical exam values.

  Up to Day 7

Secondary Outcomes (18)

• Pharmacokinetics (PK) of ASP5354 in plasma: plasma concentration at time 0 (C0)

  Before dosing on Day 1

• PK of ASP5354 in plasma: area under the concentration-time curve from time zero to 24 hours postdose (AUC0-24)

  Up to 24 hr after dosing

• PK of ASP5354 in plasma: AUC extrapolated from time to infinity as a percentage of total area under the concentration-time curve (AUCinf)

  Up to 24 hr after dosing

• PK of ASP5354 in plasma: AUC from time zero to the time of the last quantifiable concentration (AUClast)

  Up to 24 hr after dosing

• PK of ASP5354 in plasma: AUC extrapolated from time to infinity as a percentage of total area under the concentration-time curve (AUCinf(%extrap))

  Up to 24 hr after dosing

Study Arms (2)

ASP5354 Dose Escalation (5 Dose Levels)

EXPERIMENTAL

Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.

Drug: ASP5354

Placebo Dose Escalation (5 Dose Levels)

PLACEBO COMPARATOR

Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.

Drug: Placebo

Interventions

ASP5354 DRUG

Intravenous

ASP5354 Dose Escalation (5 Dose Levels)

Placebo DRUG

Intravenous

Placebo Dose Escalation (5 Dose Levels)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies:
• Not a woman of childbearing potential (WOCBP). OR
• A WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 30 days after the final investigational product (IP) administration.
• Female subject must agree not to breastfeed starting at screening, throughout the study period and for 30 days after the final IP administration.
• Female subject must not donate ova starting at screening, throughout the study period and for 30 days after the final IP administration.
• Male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 30 days after the final IP administration.
• Male subject must not donate sperm during the treatment period and for at least 30 days after the final IP administration.
• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom with spermicide for the duration of the pregnancy or time the partner is breastfeeding throughout the study period and for 30 days after the final IP administration.
• Subject agrees not to participate in another interventional study while participating in the present study.
• Subject has a body mass index range of 18.5 to 32.0 kg/m2, inclusive, and weighs \> 50 kg (for males) or \> 40 kg (for females) at screening.

You may not qualify if:

• Subject has signs of urinary tract infection, abnormalities or disease or has had operational interventions on the urinary tract.
• Subject has received any IP within 28 days or 5 half-lives (if known), whichever is longer, prior to screening.
• Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening.
• Subject has a known or suspected hypersensitivity to ASP5354 or any components of the formulation used.
• Subject has had previous exposure to ASP5354.
• Subject has any of the liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase, gamma glutamyl transferase and total bilirubin \[TBL\]) \> upper limit of normal (ULN) at day -1.
• Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration.
• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 2 weeks prior to day -1.
• Subject has any clinically significant abnormality following the physical examination, electrocardiogram (ECG) and protocol-defined clinical laboratory tests at screening or day 1.
• Subject has a mean pulse \< 45 bpm or \> 90 bpm, mean systolic blood pressure \> 140 mmHg or mean diastolic blood pressure \> 90 mmHg at day -1.
• Subject has a mean corrected QT interval using Fridericia's formula (QTcF) \> 430 msec (for males) and \> 450 msec (for females) at day 1 (as determined by the ECG machine). If the mean QTcF exceeds the limits above, 1 additional triplicate (3 measurements) ECG can be taken.
• Subject has used any prescribed or nonprescribed drugs (including vitamins, oral contraceptives, hormone replacement therapy or natural and herbal remedies \[e.g., St. John's Wort\]) in the 2 weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) or topical dermatological products, including corticosteroid products.
• Subject has smoked or has used tobacco-containing products or nicotine or nicotine containing products in the past 6 months prior to screening or the subject tests positive for cotinine at screening or day -1.
• Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within the past 2 years prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).

Sponsors & Collaborators

• Astellas Pharma Global Development, Inc.: lead

Study Sites (1)

Covance CRU, Daytona Beach

Daytona Beach, Florida, 32117, United States

Location

Study Officials

• Medical Monitor

  Astellas Pharma Global Development, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 4, 2018
• First Posted: October 9, 2018
• Study Start: October 25, 2018
• Primary Completion: May 20, 2019
• Study Completion: May 20, 2019
• Last Updated: October 16, 2024

Record last verified: 2020-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)